

## **Annual Report**

# **ALSA UK Holdings Ltd**

31 December 2019

\*\*\*\*\*\*\*

A14

11/09/2020 COMPANIES HOUSE #205

## For the period ended 31 December 2019

## **Contents**

Director's Report	3
Company Information	4
Profit & Loss	5
Balance Sheet	6
Notes	7

For the period ended 31 December 2019

## **Director's Report**

#### 1. Introduction

The Director presents the annual report including unaudited Financial Statements for ALSA UK Holdings Ltd (the "Company") for the period from inception, 18 April 2019 to the year end 31 December 2019.

The accounts have been prepared under the historical cost convention and in accordance with the Financial Reporting Standards for Smaller Entities (effective April 2008).

The principal activity of the Company is as an investment advisor in the biotechnology sector.

#### 2. Audit

For the period ended 31 December 2019, the Company was entitled to an exemption from having an audit under section 477 of the Companies Act 2006 relating to small companies.

The shareholder has not required the Company to obtain an audit of its accounts for the period in accordance with section 476 of the Companies Act 2006.

### 3. Director's Disclosures

The Director acknowledges his responsibility for complying with the requirements of the Act with respect to accounting records and preparation of the accounts. As such, these accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

No dividend was paid for the current period ended 31 December 2019.

For and on behalf of the Board of Directors:

Alek Safarian

30 JONE 2020

For the period ended 31 December 2019

## **Company Information**

#### 1. Directors

Alek Safarian (appointed 18 April 2019).

### 2. Registered Number

The Company was incorporated as a limited company in England and Wales, on 18<sup>th</sup> April 2019, with the registration number 11954152.

### 3. Registered Office

The registered office of the Company is 78 Pall Mall, London, SW1Y 5ES.

## For the period ended 31 December 2019

## **Profit & Loss**

	31 Dec 2019	
Operating Expenses		
Miscellaneous	15	
Total Operating Expenses	15	
Net Loss	(15)	

### As at 31 December 2019

## **Balance Sheet**

		31 Dec 2019
Assets		£
Investments	2	4,925.572
Current Assets		
Bank		74,414
Accounts Receivable	3	1
Total Current Assets	<del></del>	74,415
Creditors: amounts falling due within one year	4	(1)
Net Current Assets		74,414
Total Assets Less Current Liabilities		4,999,986
Creditors: amounts falling due after one year	4	(5,000,000)
Net Assets		(14)
Equity		
Current Year Loss		(15)
Ordinary Shares	5	1
Total Equity		(14)

For the period ending 31 December 2019, the Company was entitled to an exemption from having an audit under section 477 of the Companies Act 2006 relating to small companies. The shareholder has not required the Company to obtain an audit of its accounts for the period in accordance with section 476 of the Companies Act 2006. The Director acknowledges his responsibility for complying with the requirements of the Act with respect to accounting records and preparation of the accounts. As such, these accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

These Financial Statements, including the Notes, were approved by the sole director on 30 June 2020:

Alek Safarian

6 | Page

## For the period ended 31 December 2019

### **Notes**

### 1. Accounting Policies

The accounts have been prepared in accordance with the Financial Reporting Standards for Smaller Entities (effective April 2008).

The principal accounting policies applied in the preparation of these Financial Statements are set out below.

### **Basis of Preparation**

These Financial Statements have been prepared on a historical cost basis and are presented in Great British Pounds.

#### **Foreign Currencies**

Transactions in foreign currencies are recorded at the rate ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated at the rate of exchange ruling at the balance sheet date. All differences are taken to the profit and loss account.

#### Income & Expenses

All income and expenses are accounted for on an accruals basis.

#### **Going Concern**

The Director has a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. He has confirmed that the loan he has made to the Company is a long-term loan and that he has indicated he will continue to support the Company during the next 12 months and beyond. As such, the Financial Statements have been prepared on a going concern basis.

2. Investments	31 Dec 2019
Investments at Cost	£
ALSA Management Services Ltd – Loan	1,000,000
ALSA Management Services Ltd – Ordinary Share	1
Oxford Biotherapeutics Ltd	3,925,571_
Total	4,925,572

## For the period ended 31 December 2019

## Notes (Continued)

#### 3. Accounts Receivable

Accounts Receivable includes £1 receivable from the parent company, ALSA Holdings Ltd, which is due within one year.

#### 4. Creditors

Creditors includes amounts of £5,000,000, which relates to the Director's Loan, falling due after more than one year.

It also includes £1 due to the subsidiary company ALSA Management Services Ltd, payable within one year.

### 5. Share Capital

Authorised 1 Ordinary share at £1 each. Allotted, issued and fully paid 1 Ordinary share at £1 each.

#### 6. Related Party Transactions

During the period the Director Alek Safarian has provided an interest free loan to the Company of £5,000,000, which remains outstanding in full as at the year end. He has confirmed that the loan he has made to the Company is a long-term loan and that he has indicated he will continue to support the Company during the next 12 months and beyond.

### 7. Employees

The Company does not have and has not had any employees.